Table 1.
Trial and patient summary characteristics for the 102 eligible RCTs (36,058 patients) of second-line treatments for advanced NSCLC with wild-type or unknown status for EGFR
| Trial characteristics | No. of trials (%) |
|---|---|
| Phase of trial | |
| II | 48 (47) |
| III | 53 (52) |
| Unclear | 1 (1) |
| No. of centers | |
| Multi-center | 88 (86) |
| Single-center | 7 (7) |
| Unclear | 7 (7) |
| Funding source | |
| Industry | 69 (68) |
| Non-industry | 13 (13) |
| Both | 2 (2) |
| Not reported | 18 (17) |
| No. of patients (median [Q1–Q3]; mean) | 167 [105–528]; 354 |
| Line therapy | |
| Second-line only | 50 (49) |
| Second- and third-line | 41 (40) |
| Proportion of patients with third-line therapya | 31% |
| Not specified | 11 (11) |
| Population characteristics | |
| Geographic origin | |
| Most Western patientsb | 54 (53) |
| Asian patients only | 26 (25) |
| Not specified | 22 (22) |
| Proportion of Asian patientsa | 14% |
| Trials in specific histology subtype | |
| NSCC | 20 (20) |
| SCC | 4 (4) |
| Proportion of patients with SCCa | 27% |
| Molecular characteristics at baseline | |
| Unknown status for EGFR | 93 (91) |
| EGFR wild-type | 6 (6) |
| KRAS mutation | 3 (3) |
| Patient characteristicsa | |
| Age, years | 61 |
| Male | 62% |
| Stage IV cancer | 81% |
| Patients PS 2 | 8% |
| Former or current smoker | 80% |
| Patients receiving second-line treatment | 85% |
aMean over trials
b ≥ 60% of Caucasian patients
EGFR epidermal growth factor receptor, NSCC non-squamous cell carcinoma, PS Eastern Cooperative Oncology Group performance status, SCC squamous cell carcinoma